Takeda Turns To M&As To Meet Goal Of Replacing Expiring Drugs
This article was originally published in PharmAsia News
Takeda Pharmaceutical plans to acquire some companies and merge with others this year in an effort to beef up its oncology drug pipeline and stave off the impact of expiring patents. Takeda faces a problem in having two promising drugs delayed in development and marketing approval as it faces expirations on other key drugs. Takeda sees patent expiration as its "year 2010 problem" and has been counting on having replacements ready for at least two of its best-selling drugs, Prevacid (lansoprazole) for treating ulcers and Actos (pioglitazone) for diabetes, but each has faced a delay at U.S. FDA. To meet a plan to increase sales by 30 percent in fiscal 2010, Takeda now must look at cancer-fighting drugs of other makers. (Click here for more - a subscription may be required
You may also be interested in...
TOKYO - Takeda expects to launch within a month its Kapidex (dexlansoprazole) delayed- release capsules for the treatment of gastroesophageal reflux disease, the same proton pump inhibitor class of drugs as its Prevacid, which is scheduled to lose patent protection this year, according to the company's third-quarter earnings call Feb. 3
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.
GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.